American Metabolic Laboratories Logo 

 




No Prescription Required

Completely Confidential
Staff Doctor Interprets Results
COLA & CLIA Certified
Recipient of the "Award of Excellence" by COLA

     





American Metabolic Laboratories phone number

             Home of the Cancer Profile© and Longevity Profile®©       Excellence in Clinical Pathology Since 1995

Blood and urine cancer testing by Dr. E.K. Schandl, Ph.D.

The CA Profile™© includes the following tests: 

HCG IMM (Human chorianic gonadotropin) tests for intact, plus, HCG beta, core, and its fragments.  HCG is normally made by the embryonic origin trophoblast cells.  However, it may be present in most, if not all, types of cancers.  To ascertain the validity of the often very low amount of the hormone in the blood, the urine is also tested.  The tests will detect extremely low levels of the hormone in the blood and the urine, and are specific for HCG 98-99%.  Dr.Schandl named this tumor marker "the pregnancy and malignancy hormone."  HCG is an immunity suppressor and it initiates and enhances DNA, RNA, and protein synthesis.  Generally, it is produced under anaerobic cellular conditions by trophoblasts in pregnancy and in malignancy.  The analytical sensitivity, i.e. lowest detectable level of the test is 0.4 mIU/mL for the serum and urine alike..

The HCG Urine  test was studied and introduced at American Metabolic Laboratories. This test is an important constituent of our Cancer Profile. It must be noted that American Metabolic Laboratories' Urine-HCG Test may be the one and only one of its kind for being quantitative down to less than 1.1 mIU/mL detection level. This test, unlike Doctor Navarro's for instance, requires about 0.5 mL of urine without any treatment, in its natural form. It is totally specific for the HCG hormone even in minute quantities. The Navarro method requires acetone denaturation and extraction that possibly yields a conglomerate of HCG, LH, FSH, and TSH hormones. All of the four structurally very similar hormones are precipitated by the harsh treatment and will add on to the reported HCG value. Postmenopausal women and older men with high LH and/or FSH, and hypothyroid individuals with high TSH may yield elevated "HCG" values.  However, this hormone species is actually HCG-like (HCG-L) with one-half biological activity when compared to pregnancy or tumor generated HCG.

PHI enzyme channels cells into anaerobic fermentation metabolism.  This kind of cellular survival is what cancer cells favor.  The more energy generating metabolic pathway of normal cells is oxidative phosphorylation in the presence of adequate amounts of oxygen.  This is the pathway normal cells utilize. Hence, more oxygen is less cancer, and less oxygen is more cancer.  PHI is a neurokine also called the autocrine motility factor (AMF), i.e. malignancy/cancer spreading factor.   Interestingly and importantly, it is an inhibitor of HER 2, a breast cancer therapeutic drug.  Surgery and biopsy, as well as the PHI enzyme (a.k.a. GPI and PGI) may contribute to metastasis.
        
CEA is a broad spectrum cancer marker. It is the carcinoembryonic antigen. It can be elevated in all sorts of cancers. It is very prevalent in cancers of the breast, colon, and rectum. Like all the others, it is an independent cancer marker that by itself may be sufficient as a diagnostic adjunct.   

GGTP is the most sensitive test for the liver, however, it may be elevated in diseases of the heart, lungs, and kidneys. It is not a tumor marker, however, it may be elevated in cancer patients as a result of either cancer spread or toxic therapy. 
  

TSH or thyroid stimulating hormone regulates basic metabolic rate, i.e. oxygen utilization. A high level, i.e. hypothyroidism, may be a prelude to cancer. Chemotherapy frequently causes this anaerobic condition by injuring the thyroid gland.   

DHEA-S is the "adrenal anti stress, pro immunity, longevity hormone", according to Dr. Schandl. The immune system is impaired without adequate amounts of this hormone. Most, if not all cancer patients and those in the process of developing cancer have very low or no DHEA in their blood.   DHEA is a requirement for T-lymphocyte,T-cell, production by the Thymus gland.

           


 HCG IMM




May be elevated in cancer, stress-related to cancer, a developing cancer, or pregnancy.  It may also be elevated without cancer diagnosis in peri/post menopausal women and men with abnormally low testosterone.  It measures intact, beta, and all other molecular forms of the hormone, including HCG-LS (HCG-like substance)  This molecular entity also posses tumorigenic activity.   
Normal: Less than 1mIU/mL; gray zone: up to 3.0 mIU/mL



 HCG Urine
It is another, may be a confirmatory test for HCG in cancer or developing cancer, similarly as above.  Some authorities consider Urinary HCG test of great importance for diagnosis and prognosis. 
Normal: 0.0 - 1.0; gray zone 1.1 - 3.8 mIU/mL
PHI
 Elevations may indicate the propensity of developing and spreading cancer.  It can be elevated in cancer; acute viral disease, acute heart, liver, or muscle disease.
 Normal: Less than 34 U/L; gray zone: up to 40.00 U/L
 GGTP Diseases of the liver, pancreas, and the biliary system.  Also heart, lung, kidney ailments
 Normal: Females less than 29 IU/L, Males less than 35 IU/L
 TSH Thyroid stimulating hormone, for thyroid and oxygen metabolism. 
This ultra sensitive method measures low or high thyroid activity.  A high TSH is a hypothyroid condition and a low TSH is a hyperthyroid condition.

 Normal: 0.4 - 4.0 mcIU/mL
 DHEA-S



Adrenal anti-stress, immunity, and longevity hormone; low or zero in most cancer patients.  It is also important for T-Cell production by a Thymus gland.


 Normal: Females 35 - 430 mcg/dL, Males 80-560 mcg/dL. Results must be interpreted in reference to a person's age
 CEA Carcinoembryonic antigen is a broad-spectrum tumor marker that may be elevated in any malignancy.  
 Normal: Less than 3.0 ng/mL; gray zone is 3.1 - 5.0 ng/mL

          HCG, PHI, CEA are independent cancer markers.  They are not organ nor site specific.